Full Length Research Paper
References
|
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P (2014).Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New England Journal of Medicine 370(16):1483-1493. |
|
|
Enel C, Loû AD, Yoman TD, Danel C, Larmarange J (2015).Viral hepatitis B and C in Côte d'Ivoire: the urgency of a revitalization of the fight. African Journal of Hepato-Gastroenterology 9(3):94-98. |
|
|
Feray C. (2015). L'hépatite B en Afrique: une épidémie oubliée. Humanitaire 40:68-73. URL : |
|
|
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales F L, Craxi A (2002).Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 347(13):975-982. |
|
|
Fried MW, Shiffman ML, Reddy RK, Smith C, Marino G, Goncales F, Hoffman J (2001).Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. Gastroenterology 120(5):55. |
|
|
Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, Pang PS (2014). Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 146(3):736-743. |
|
|
Hézode C, De Lédinghen V, Fontaine H, Zoulim F, Lebray P, Boyer N, Larrey D, Silvain C, Botta-Fridlund D, Leroy V, Bourlière M, D'alteroche L, Fouchard-Hubert I, Guyader D, Rosa I, Nguyen-khac E, Di Martino V, Carrat F, Fedchuk L, Akremi R, Bennai Y, Bronowicki JP (2015). Daclatasvir plus Sofosbuvir avec ou sans ribavirine chez les patients de génotype 3: résultats préliminaires de l'ATU de cohorte Daclatasvir. Journées de l'AFEF. Communication affichée 01. |
|
|
Hutin Y, Desai S, Bulterys M (2018). Prévention de l'infection par le virus de l'hépatite B : étapes et cibles. Bulleltin de l'Organisation Mondiale de la Santé 96:443A. |
|
|
Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Rustgi V (2014).Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New England Journal of Medicine 370(20):1879-1888. |
|
|
Lawitz E., Poordad F.F., Pang P.S., Hyland R.H., Ding X., Mo H., Symonds WT, McHutchison JG, Membreno FE (2014). Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in the treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 383(9916):515-523. |
|
|
Perrillo RP (2006). Therapy of hepatitis B - viral suppression or eradication? Hepatology 43(1):182-193. |
|
|
Programme National de Lutte contre les Hépatites Virales : National Control Program of Viral Hepatitis (PNLHV). (2017). Prise en charge du cancer et des Hépatites Virales dans le cadre des Programmes « Accès Roche-Cancer du sein » et « Accès Roche-Hépatites virales ». Décision N° 1682 portant avenant du 09 octobre 2017. |
|
|
Société Nationale Française d'Gastro-Entérologie (SNFGE). (2015). Abrégé d'hépato-gastro-entérologie et de chirurgie digestive : Partie « Connaissances », 3rd edn. Paris : Elsevier-Masson; 20p. |
|
|
World Health Organization (2014). Screening, care and treatment of persons with chronic hepatitis C infection: WHO guidelines 2014. |
|
|
World Health Organization (2016). New recommendations in the updated WHO guidelines for the screening, care and treatment of persons with chronic hepatitis C infection: policy brief. World Health Organization. View |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
